Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARDINAL HEALTH INCCAH · Entity 3014 | Director | November 09, 2022 | November 10, 2022 |
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | January 02, 2025 | January 06, 2025 |
| Organon & Co.OGN · Entity 4115 | Director · Executive Chair | November 12, 2025 | November 13, 2025 |
| Solventum CorpSOLV · Entity 1645 | Director | May 15, 2026 | May 18, 2026 |
| TEXAS INSTRUMENTS INCTXN · Entity 2834 | Director | May 13, 2026 | May 14, 2026 |
| electroCore, Inc.ECOR · Entity 6900 | Director | June 07, 2019 | June 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARDINAL HEALTH INC
Report date November 09, 2022 · Filed November 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 41,631 |
Reported balance
After 2022-11-09 transaction · row 1
1 source rowRow 1 · 2022-11-09 · Grant · Acquired 2,308 · Balance 41,631 F1: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders.
Cartesian Therapeutics, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,629 |
Reported balance
After 2025-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 2,600 · Balance 15,629 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.93 · Expires 2035-01-01 | Direct | 8,000 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 8,000 · Balance 8,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2034-01-01 | Direct | 8,266 |
Reported balance
Holding disclosure · report date 2025-01-02 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 8,266 F3: This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027. F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3: This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.
Organon & Co.
Report date November 12, 2025 · Filed November 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectIRA | 77,869 |
Reported balance
After 2025-11-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-11-12 · Purchase · Acquired 65,400 · Balance 77,869 F1: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Solventum Corp
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,848 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 4,848 · Balance 4,848 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
TEXAS INSTRUMENTS INC
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,626 |
Ending reported balance
After 2026-05-13 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-05-13 · Exercise / conversion · Acquired 4,306 · Balance 41,932 Row 2 · 2026-05-13 · Exercise / conversion · Acquired 4,532 · Balance 46,464 Row 3 · 2026-05-13 · Sale · Disposed 8,393 · Balance 38,071 F1: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. Row 4 · 2026-05-13 · Sale · Disposed 445 · Balance 37,626 F2: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. |
| NQ Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $110.15 · Expires 2028-01-25 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-13 · Exercise / conversion · Disposed 4,306 · Balance 0 F3: The option became exercisable in four equal annual installments beginning on January 25, 2019. |
| NQ Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.41 · Expires 2029-01-25 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-13 · Exercise / conversion · Disposed 4,532 · Balance 0 F4: The option became exercisable in four equal annual installments beginning on January 25, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.
F2: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.
F3: The option became exercisable in four equal annual installments beginning on January 25, 2019.
F4: The option became exercisable in four equal annual installments beginning on January 25, 2020.
electroCore, Inc.
Report date June 07, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-06-08 | Direct | 66,964 |
Reported balance
After 2019-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-07 · Grant · Acquired 66,964 · Balance 66,964 F1: The Deferred Stock Units vest upon the close of business on the day before the next annual meeting of stockholders following the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The Deferred Stock Units vest upon the close of business on the day before the next annual meeting of stockholders following the date hereof.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-30 · Disposition to issuer · Disposed 8,000 · Balance 10,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.93 · Expires 2028-08-09 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019. F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019.
F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 39,535 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2021-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2022-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.06 · Expires 2023-06-12 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 900 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 1,454 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 6,200 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-20 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-11-20 · Disposition to issuer · Disposed 1,125 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Merck & Co., Inc.
Report date November 03, 2009 · Filed November 04, 2009
Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 1
1 source rowRow 1 · 2009-11-03 · Disposition to issuer · Disposed 169,534 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2009-11-03 · Disposition to issuer · Disposed 375,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2009-11-03 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-11-03 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-11-03 · Disposition to issuer · Disposed 270,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-11-03 · Disposition to issuer · Disposed 264,600 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Phantom Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2009-11-03 · Disposition to issuer · Disposed 66,552.22 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Each unit of phantom stock is the economic equivalent of one share of common stock.
F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 8,500 | $30.61 | $260,185.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 25 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,705 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 16,900 | $30.66 | $518,154.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 24 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,205 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 14,400 | $30.67 | $441,648.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 23 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,105 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 5,800 | $30.68 | $177,944.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 22 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,505 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 2,500 | $30.69 | $76,725.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 21 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,305 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 800 | $30.70 | $24,560.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 20 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,805 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 7,400 | $30.71 | $227,254.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 19 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,605 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 4,000 | $30.80 | $123,200.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 18 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,005 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 500 | $30.81 | $15,405.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 17 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,005 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 16,700 | $30.82 | $514,694.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 16 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,505 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 13,200 | $30.86 | $407,352.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 15 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,205 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 22,800 | $30.87 | $703,836.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 14 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,405 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 14,600 | $30.88 | $450,848.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 13 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,205 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 42,800 | $30.89 | $1,322,092.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 12 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,805 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 39,300 | $30.90 | $1,214,370.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 11 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,605 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 31,400 | $30.91 | $970,574.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 10 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,905 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 155,300 | $30.92 | $4,801,876.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 9 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,305 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 11,700 | $30.93 | $361,881.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 8 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,605 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 3,700 | $30.94 | $114,478.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 7 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,305 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 2,300 | $30.95 | $71,185.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 6 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,005 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 3,000 | $31.01 | $93,030.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 5 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,305 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 200 | $31.03 | $6,206.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 4 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,305 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 500 | $31.05 | $15,525.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,505 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | SaleCommon Shares | 1,200 | $31.06 | $37,272.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,005 Read SEC document |
| April 20, 2007 Filed Apr 24, 2007 20:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 450,000 | $18.20 | $8,190,000.00 |
DisclosureSEC source: 0000310158-07-000014 · cox603.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2007 Filed Jan 22, 2007 23:52 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | GrantNQ Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $28.32 | $0.00 |
DisclosureSEC source: 0000097476-07-000022 · doc.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2017-01-18 F2 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on January 18, 2008. Read SEC document |
| January 18, 2007 Filed Jan 22, 2007 23:52 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000097476-07-000022 · doc.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 F1 · kind: Award of restricted stock units granted under the Texas Instruments 2003 Director Compensation Plan. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 15:31 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 70,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-06-000149 · cox580.xml · derivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Shares · 70,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 15:31 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 32,445 | $21.93 | $711,518.85 |
DisclosureSEC source: 0000310158-06-000149 · cox580.xml · nonDerivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,205 Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 15:31 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-06-000149 · cox580.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| May 19, 2006 Filed May 23, 2006 21:08 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 375,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0000310158-06-000072 · cox534.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Shares · 375,000 shares Expires 2013-05-18 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan and exerciseable in one-third increments on April 1 of 2007, 2008 and 2009. The vesting of 75,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. Read SEC document |
| May 19, 2006 Filed May 23, 2006 21:08 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 70,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-06-000072 · cox534.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Shares · 70,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan. All of the shares become deliverable on April 1, 2009 subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| May 15, 2006 Filed May 16, 2006 10:44 UTC | Merck & Co., Inc. SGP · Entity 2807 | OtherCommon Shares | 46,350 | $20.10 | $931,635.00 |
DisclosureSEC source: 0000310158-06-000031 · cox531.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,650 F1 · kind: Stock withheld to pay tax liability for the vesting of 100,000 restricted stock awards granted on May 14, 2003. Read SEC document |
| January 19, 2006 Filed Jan 24, 2006 01:17 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | GrantNQ Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $32.55 | $0.00 |
DisclosureSEC source: 0000097476-06-000032 · doc.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2016-01-19 F1 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on January 19, 2007. Read SEC document |
| April 25, 2005 Filed Apr 27, 2005 19:42 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 400,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0000310158-05-000016 · cox474.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2015-04-24 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on April 26 of each 2006, 2007 and 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005 with respect to 80,000 option shares. Read SEC document |
| April 25, 2005 Filed Apr 27, 2005 19:42 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 76,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-05-000016 · cox474.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Shares · 76,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on April 25, 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 31, 2005 Filed Feb 1, 2005 23:46 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | PurchaseCommon Stock | 425 | $23.01 | $9,779.25 |
DisclosureSEC source: 0000097476-05-000052 · doc.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,865 Read SEC document |
| January 20, 2005 Filed Jan 24, 2005 21:08 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | GrantNQ Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $21.55 | $0.00 |
DisclosureSEC source: 0000097476-05-000026 · doc.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2015-01-20 F1 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on January 20, 2006. Read SEC document |
| October 21, 2004 Filed Oct 25, 2004 20:37 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | PurchaseCommon Stock | 440 | $22.94 | $10,093.60 |
DisclosureSEC source: 0000097476-04-000045 · doc.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,440 Read SEC document |
| September 16, 2004 Filed Sep 17, 2004 21:53 UTC | TEXAS INSTRUMENTS INC TXN · Entity 2834 | OtherCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097476-04-000031 · doc.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Award of restricted stock units granted under the Texas Instruments 2003 Director Compensation Plan. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantPhantom Stock Units · Derivative | 372,034 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-04-000038 · cox366.xml · derivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,034 Underlying: Common Shares · 372,034 shares Expires not disclosed F7 · derivative.exercise_price: 1 for 1 F9 · price: Not Applicable. F8 · derivative.exercise_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. F8 · derivative.expiration_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (Right to Buy) · Derivative | 450,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0000310158-04-000038 · cox366.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Shares · 450,000 shares Expires 2014-02-22 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on February 24 of each 2005, 2006 and 2007. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 70,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-04-000038 · cox366.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on February 23, 2007. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.